The small study, published recently in the journal Obesity, looked at 34 patients who had already lost weight on GLP-1 ...

SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults, the US drugmaker said on WeChat on Friday, boosting ...

Ecnoglutide is distinguished by its selective activation of the cAMP signalling pathway, reducing β-arrestin recruitment.

作为先为达生物自主研发的新一代cAMP偏向型GLP-1受体激动剂，埃诺格鲁肽注射液凭借独特的偏向性机制，已在多项临床研究中展现出了优异的疗效与安全性，其中国人群经安慰剂组调整后的平均体重降幅达15.1%，92.8%的患者达到具有临床意义的体重下降，超 ...

Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced today that China's ...

New research is taking a closer look at what can happen when people stop taking GLP-1 medications for a long period of time.

A newly reported side effect of the popular GLP-1 weight loss drugs may be its most annoying yet. From “Ozempic ears” and ...

据悉根据上述协议，辉瑞将获得该产品在中国大陆的独家商业化权益，迈出其全球代谢领域战略布局在中国的第一步；同时先为达生物为许可产品的药品上市许可持有人（MAH），负责许可产品的研发、注册、生产及供应。先为达生物将有权获得辉瑞支付的最高可达4.95亿美元的付款总额，包括首付款、注册及销售里程碑付款。

As states cut Medicaid coverage for GLP-1 drugs, access to obesity treatment is increasingly tied to income—raising questions for both Medicaid and Medicare.

GoodRx reports that GLP-1 medications will expand in use and accessibility, with new oral options and evolving insurance ...

Uncrowned is a new destination for all things MMA, boxing, wrestling, and more, featuring Ariel Helwani. But injectable medications aren’t right for everyone. That’s where a new wave of oral GLP-1 ...